Clotted Apheresis Hematopoietic Stem Cell Product Authors: Lefan Zhuang, Jennifer Woo, Franchesca Francisco, Rickey Bertram, Shirong Wang, Ryan Jackson, Shan Yuan Published: 2024 ABSTRACT ABSTRACTThe majority of the time hematopoietic progenitor cells (HPC) are collected through leukapheresis, where anticoagulants are necessary to prevent clotting of the apheresis circuit and HPC product. Although clotting of the product is a possible rare complication surrounding the HPC cryopreservation process, there have been no reports of clotting of fresh HPC product after collection. We report a case of progressive clotting of a fresh matched unrelated donor HPC product. Upon initial receipt, thin thread‐like white clots were seen in the bag. In an attempt to isolate the clot, the product was aseptically aliquoted into 50 mL syringes. Within the next 60 minutes the small clots coalesced into a pink cylindrical jelly‐like blood clot surrounded by serum. In the future, an anticoagulant can be added into the product prior to isolation of the clot. List of Abbreviations Deutsche Knochenmarkspenderdatei hematopoietic progenitor cell Hematopoietic progenitor cell (HPC) transplant is a treatment for many patients with hematopoietic malignancies. Most of the time HPCs are collected through leukapheresis, where anticoagulants are necessary to prevent clotting of the apheresis circuit and HPC product. Although clotting is a possible rare complication surrounding the HPC cryopreservation process [1, 2, 3], there have been no reports of clotting of fresh HPC product after collection. This case report was approved by the IRB and informed consent was waived. Our medical center received a fresh apheresis HPC product from Deutsche Knochenmarkspenderdatei (DKMS) Collection Center in December 2023. It was collected from a 36‐year‐old female matched unrelated donor, and transported to us over 37 hours at 2°C–6°C. Upon receipt 39 hours after collection, the product was found to be effectively packaged, and reported by DKMS to be 649.7 mL with 7.72 × 106 CD 34+ cells/kg recipient weight and 100% viability. The reported total nucleated count was 1191.42 × 106. On visual examination of the product, there were a few branched thin thread‐like white clots in the bag. The bag was intact and not leaking, the label was correct, and the product color was normal with no evidence of hemolysis or bacterial contamination. Samples from the product bag were sent to the hematology, flow cytometry, and microbiology laboratories for testing. The product was weighed, and the laboratory technician tried to isolate the clot by aseptically aliquoting the product into multiple 50 mL syringes. Twenty minutes after transfer of the product into the syringes, more small white clots began to form (Figure 1). The technician attempted to place the product back into the bag from the syringes, but it was not possible due to the clots. Within the next 40 minutes the small clots coalesced into a pink cylindrical jelly‐like blood clot surrounded by serum in all the syringes (Figure 2). The samples sent earlier to the labs for testing were discovered to have formed clots preventing laboratory measurements. An investigation done by National Marrow Donor Program failed to demonstrate any abnormalities during the collection, processing, or transport of the product. No additional donor testing was done. DKMS reported the product contained 53.9 mL of anticoagulant citrate dextrose solution, Solution A and 275.0 IU of heparin. Trypan blue staining for viability was not performed upon receipt. The product was not infused to the intended recipient and an urgent donor search was initiated. Initial clots after transfer of the product into syringes. Within 1 hour of transferring the HPC product into syringes, the small clots coalesced into a pink cylindrical jelly‐like blood clot surrounded by serum. There can be multiple causes of the clotting including defect in anticoagulant, clotting abnormalities in donor, or inappropriate blood to anticoagulant ratio [1, 2, 3, 4, 5]. Transfer of the product from the bag to the syringe led to significant additional activation of the hemostatic system. Although it is not common to observe clots in a stem cell product, in the future, an anticoagulant could be tried to possibly mitigate this issue prior to isolation of the clot. Conflicts of Interest The authors declare no conflicts of interest. Funding: The authors received no specific funding for this work. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.